Key result
Catheter ablation achieves ~96% acute success in pediatric Wolff-Parkinson-White syndrome.
Why the study?
In fetal and pediatric patients, ventricular preexcitation, Wolff-Parkinson-White syndrome, and paroxysmal supraventricular tachycardia can cause severe symptoms including heart failure and sudden cardiac death, frequently requiring risk stratification and treatment.
Provides comprehensive clinical recommendations for the diagnosis, sudden cardiac death risk stratification, pharmacological management, transcatheter ablation, and sports eligibility in fetal and pediatric patients (≤12 years) with WPW syndrome and accessory pathways.
Answers are grounded in this paper and cite their sources.
Guides therapy selection in pediatric WPW; leaves open randomized comparisons of ablation versus class IC agents.
Overt or concealed accessory pathways are the anatomic substrates of ventricular preexcitation (VP), Wolff-Parkinson-White syndrome (WPW) and paroxysmal supraventricular tachycardia (PSVT). These arrhythmias are commonly observed in pediatric age. PSVT may occur at any age, from fetus to adulthood, and its symptoms range from none to syncope or heart failure. VP too can range from no symptoms to sudden cardiac death. Therefore, these arrhythmias frequently need risk stratification, electrophysiologic study, drug or ablation treatment. In this review of the literature, recommendations are given for diagnosis and treatment of fetal and pediatric age (≤12 years) WPW, VP, PSVT, and criteria for sport participation.
No takes yet. Share an insight, caveat, or question.
Leoni et al. (2023) conducted a review in Wolff-Parkinson-White syndrome, ventricular preexcitation, and paroxysmal supraventricular tachycardia. Antiarrhythmic drug therapy, electrophysiological study, and transcatheter ablation was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: